The DDX10 gene fuses with the NUP98 gene to form the chimeric gene NUP98‐DDX10,9 which is involved in de novo or secondary myeloid malignancies10, 11 as well as imatinib resistance.12 The multiplication and self‐renewal of primary human CD34+ cells can also be highly accelerated by NUP98‐DDX10.13 Dysregulation of DDX32 expression has been demonstrated in lymphoid neoplasms,14, 15 suggesting that this gene may contribute to carcinogenesis. Here, DDX10 is linked to lymphoid neoplasm.